All results
1 results for chemotherapy or without bortezomib newly diagnosed t all and t cell lymphoblastic
-
Clinical TrialsInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia…